Publication: Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure.
No Thumbnail Available
Identifiers
Date
2016-09-23
Authors
Gonzalez-Serna, A
Genebat, M
De-Luna-Romero, M
Tarancon-Diez, L
Dominguez-Molina, B
Pacheco, Y M
Muñoz-Fernandez, M A
Leal, M
Ruiz-Mateos, E
Advisors
Journal Title
Journal ISSN
Volume Title
Publisher
American Society for Microbiology
Metrics
Export
Abstract
TROCAI is a phenotypic tropism test developed using the virological response to a short-term exposure to maraviroc monotherapy (Maraviroc Clinical Test [MCT]). It was found that with TROCAI, a cutoff of <0.5% of dual/mixed viruses was needed to predict R5 HIV tropism. Here, we have validated TROCAI, using this cutoff, in a new cohort of 42 patients, finding a very high concordance between TROCAI and MCT (98%), and a good concordance (71 to 87%) with other genotypic/phenotypic methods.
Description
MeSH Terms
Cyclohexanes
HIV
HIV Fusion Inhibitors
Humans
Inhibitory Concentration 50
Maraviroc
Triazoles
Viral Tropism
Virology
HIV
HIV Fusion Inhibitors
Humans
Inhibitory Concentration 50
Maraviroc
Triazoles
Viral Tropism
Virology
DeCS Terms
VIH
Tropismo viral
Monoterapia
Pruebas fenotípicas
Resistencia a medicamentos antirretrovirales
Carga viral
Validación clínica
Tropismo viral
Monoterapia
Pruebas fenotípicas
Resistencia a medicamentos antirretrovirales
Carga viral
Validación clínica
CIE Terms
Keywords
HIV tropism, Maraviroc, Monotherapy, Phenotypic test, Virological response, HIV drug resistance, Diagnostic accuracy
Citation
Gonzalez-Serna A, Genebat M, De Luna-Romero M, Tarancon-Diez L, Dominguez-Molina B, Pacheco YM, et al. Validation of the HIV Tropism Test TROCAI Using the Virological Response to a Short-Term Maraviroc Monotherapy Exposure. Antimicrob Agents Chemother. 2016 Sep 23;60(10):6398-401.